Clinical Trial Update: Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years [Phase 2]

View source ↗

Summary

Phase 2 trial assessing immune interference from MenABCWY vaccine in healthy subjects aged 10-25; completed with posted results in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Disease

Drugs mentioned

• MenABCWY

Snippet

Sponsor: GlaxoSmithKline | Conditions: Meningitis, Meningococcal | Phase 2 | Status: COMPLETED | Results posted: 2020-01-02